Evidence mapPaperPMID 41465472Full record

SynthesisInternational journal of molecular sciences2025

Cross-Study Meta-Analysis of Blood Transcriptomes in Type 2 Diabetes.

Aleksandr A Tkachenko, Ziravard N Tonyan, Yulia A Nasykhova, Yury A Barbitoff, Iaroslav N Renev, Maria M Danilova, Anastasiia A Basipova, Olga B Glavnova, Dmitrii E Polev, Sergey V Chepanov and 4 more

Abstract readMeta-Analysis
In one paragraph

Synthesis in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Aleksandr A TkachenkoD.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, Mendeleevskaya Line 3, 199034 Saint Petersburg, Russia.
Ziravard N TonyanD.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, Mendeleevskaya Line 3, 199034 Saint Petersburg, Russia.ORCID 0000-0001-9050-5886
Yulia A NasykhovaD.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, Mendeleevskaya Line 3, 199034 Saint Petersburg, Russia.ORCID 0000-0002-3543-4963
Yury A BarbitoffD.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, Mendeleevskaya Line 3, 199034 Saint Petersburg, Russia.
Iaroslav N RenevD.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, Mendeleevskaya Line 3, 199034 Saint Petersburg, Russia.
Maria M DanilovaD.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, Mendeleevskaya Line 3, 199034 Saint Petersburg, Russia.ORCID 0000-0002-3656-230X
Anastasiia A BasipovaD.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, Mendeleevskaya Line 3, 199034 Saint Petersburg, Russia.ORCID 0000-0002-5020-9561
Olga B GlavnovaD.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, Mendeleevskaya Line 3, 199034 Saint Petersburg, Russia.
Dmitrii E PolevD.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, Mendeleevskaya Line 3, 199034 Saint Petersburg, Russia.ORCID 0000-0001-9679-2791
Sergey V ChepanovD.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, Mendeleevskaya Line 3, 199034 Saint Petersburg, Russia.
Sergey A SelkovD.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, Mendeleevskaya Line 3, 199034 Saint Petersburg, Russia.
Nikita V GolovkinSt. Martyr George City Hospital, 194354 Saint Petersburg, Russia.
Margarita E VlasovaSt. Martyr George City Hospital, 194354 Saint Petersburg, Russia.
Andrey S GlotovD.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, Mendeleevskaya Line 3, 199034 Saint Petersburg, Russia.ORCID 0000-0002-7465-4504

Funding

Ministry of Science and Higher Education of the Russian Federation 075-15-2021-1058
6 · The paper itself

Abstract

Type 2 diabetes (T2D) is a chronic metabolic disorder with an estimated prevalence of over 422 million individuals affected globally. Since the advent of genomics, numerous studies have been conducted to elucidate T2D pathogenetic mechanisms and define genetic loci affecting T2D susceptibility. Transcriptomic studies, including bulk and single-cell RNA sequencing, play an important role both in discerning molecular mechanisms of the disease and in identifying potential T2D biomarkers. In this study, we performed bulk RNA-seq of whole blood of nine T2D patients and nine control subjects and performed meta-analysis of these data with seven publicly available blood RNA-seq datasets of T2D patients. Our analysis showed that the changes in the gene expression between different studies show very low concordance; moreover, a substantial number of differentially expressed genes (DEGs) was identified in only three out of eight datasets, with only five DEGs-

Indexed as

Diabetes Mellitus, Type 2TranscriptomeBiomarkersFemaleGene Expression ProfilingHumansMaleBiomarkersblood transcriptomeexpression profilingmeta-analysisRNAseqRNA sequencingtype 2 diabetes

Identifiers

PMID41465472
PMCPMC12732418

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.